Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma ...Middle East

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent CHICAGO, June 3, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson...

Hence then, the article about janssen presents longer term talquetamab follow up data showing overall response rates of more than 70 percent in heavily pretreated patients with multiple myeloma was published today ( Saturday 03/06/2023 - 10:41 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma )

Also on site :

• ‘The Final Girl Support Group’ Heads To Paramount As Feature To Be Directed & Adapted By Christopher Landon; Aperture & Muschiettis’ Double Dream Producing
• Marc Blumberg Arrested for Lewd Acts on a Child While Working at Moorpark Equestrian Facility; Additional Survivors Expected
• Inside China’s two-speed economy: Why goods consumption is slumping even as exports and services boom